CELLUMED (049180) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, CELLUMED (049180) reported revenue of 140.2 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025140.2 billion KRW-5.1 billion KRW-2.2 billion KRW[source]
2024129.1 billion KRW-6.8 billion KRW-31.8 billion KRW[source]
202395.6 billion KRW-10.5 billion KRW-37.9 billion KRW[source]
2022122.1 billion KRW-2.7 billion KRW-5.4 billion KRW[source]
202199.9 billion KRW4.7 billion KRW8.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202538.5 billion KRW26.3 billion KRW12.2 billion KRW[source]
202446.6 billion KRW33.1 billion KRW13.5 billion KRW[source]
202355.2 billion KRW27.2 billion KRW28.0 billion KRW[source]
202272.3 billion KRW21.8 billion KRW50.6 billion KRW[source]
202172.7 billion KRW27.3 billion KRW45.5 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025-3.9 billion KRW-6.9 billion KRW8.2 billion KRW[source]
2024-419 million KRW-4.4 billion KRW8.2 billion KRW[source]
2023-5.4 billion KRW-7.6 billion KRW9.2 billion KRW[source]
2022-8.3 billion KRW-4.6 billion KRW2.2 billion KRW[source]
2021-2.7 billion KRW-18.9 billion KRW31.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-30 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · EPS, DPS, and dividend yield are DART disclosure values. PER is calculated as closing price / disclosed EPS · This page provides factual information, not investment advice